GlassScriptPhysician profile
Shanda D Carter
NPI 1023485935
$6,344.30
in general payments reported to CMS, 2019-2025
17 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $719 · 2023: $1,158 · 2024: $1,740 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,845 · Education: $81.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.58 |
| Education | $81.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,666.09 | 2021-2025 | |
| Janssen Biotech, INC. | $1,092.05 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $800.48 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $689.86 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $585.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $487.47 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $255.03 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $245.71 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $92.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $88.04 | 2022-2025 | |
| Dermavant Sciences, INC. | $85.85 | 2023-2024 | Vtama |
| Incyte Corporation | $67.53 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $43.80 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $42.35 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $41.03 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $40.52 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanda Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.